A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Iniparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
Indications Solid tumours
Focus Adverse reactions

21 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
16 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
16 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com